Nav: Home

Will unanticipated genetic mutations lead to subsequent disease?

November 09, 2016

A study published Nov. 9 in the journal Science Translational Medicine is the first to show that mutations in certain cancer and cardiovascular genes put individuals at an increased risk for dominantly inherited, actionable conditions, regardless of family medical history. The study, carried out in two separate populations of African-Americans and European-Americans, finds that individuals carrying these mutations are at higher risk for developing one of these cancer or cardiac syndromes, respectively. The new work, led by Robert C. Green, MD, MPH, of Brigham and Women's Hospital, Broad Institute and Harvard Medical School, has important implications for the use of genomic sequencing as a future clinical screening tool.

"The field of clinical genetics has been uncertain about recommending genome screening in healthy individuals for two reasons. First, we do not know if those individuals will be at increased risk regardless of their family history. Second, we do not know if identifying individuals carrying these mutations will make a positive difference in their eventual clinical outcomes," said Green, senior author on the research. "This analysis addresses only the first of these questions, but demonstrates that in the aggregate, mutations in a subset of genes are associated with a substantial risk of developing the related condition."

The study combined the work of investigators in genomics, informatics, molecular biology, epidemiology and statistics at multiple institutions to seek insights into a question that has been extremely difficult to answer. If people carry a genetic mutation, what are the chances that they will develop the related condition over a number of years? Addressing this question has been difficult because very few population-based cohorts have had both genetic sequencing and systematic medical testing recorded over time, and highly heritable conditions are relatively rare.

To explore this question, the investigators used data previously collected in two longitudinal cohort studies that investigated heart disease but also collected data on cancer. Data were analyzed from 462 European-Americans from the Massachusetts-based Framingham Heart Study who had been followed for two decades, and 3,223 African-American participants in the Mississippi-based Jackson Heart Study who had been followed for a shorter period. The researchers screened participants for disease-causing mutations using a panel of 56 genes representing 24 hereditary cancer and cardiac syndromes while blinded to the clinical outcomes in these participants. The researchers also collected clinical and diagnostic test information on the participants while blinded to the genome sequencing results.

The research team then analyzed whether those who carried the mutations went on to develop associated conditions (cancer, heart disease and high cholesterol) more frequently than those who did not carry the mutations. The results were highly significant, indicating that carrying a mutation in one of the 56 genes conferred greater risk of eventually developing an associated disease in both African-Americans and European-Americans. The risk differences were not thought to be due to racial differences, but rather to the fact that the European Americans in the Framingham study were followed longer than the African Americans in the Jackson study, and had more time to develop the clinical features associated with their genetic changes. Importantly, the study combined risks from very different mutations and very different genes into an "aggregate" estimation of the genetic penetrance (the likelihood that someone with a mutation will develop the condition). While these results establish that as group, those who carry one of these mutations have a higher risk to develop the related disease than those who do not, the results are less relevant to individuals within that population. Nevertheless, it is the first such study to attempt to estimate the effects of such aggregate penetrance within a group.

"These populations are uniquely suited for a study like this because everyone in the Framingham and Jackson cohorts received regular EKGs, echocardiograms and lipid measurements, not just those who had medical problems," said Pradeep Natarajan, MD, MMSc, one of the lead authors based at Massachusetts General Hospital. "Data of this nature is not available from a typical health care system where only those who have come to medical attention get blood testing or certain types of diagnostic testing."

Eventually, using an individual's genomic variants to predict and prevent future illness may become a routine part of health care. However, it remains to be seen whether identifying individuals with genetic mutations will result in sufficient clinical benefit to merit the risks and costs of downstream imaging studies or procedures. The authors caution that this study does not provide evidence that recognizing genetic mutations directly confers medical benefit. In seeking to explore the related question of clinical outcomes, Green and his team have also implemented a separate randomized clinical trial of medical sequencing called the MedSeq Project, and have organized a Consortium to track medical outcomes among any ostensibly healthy individuals who have been sequenced for predictive purposes.
-end-
In addition to Natarajan, lead authors on the study included Alexander Bick, MD, PhD, of Massachusetts General Hospital, and Nina Gold, MD, of Boston Children's Hospital. The study involved screening thousands of variants from each person's genome, followed by rigorous manual classification of the variants, supervised by Heidi Rehm, PhD, FACMG, director of the Partners Laboratory for Molecular Medicine and a clinical molecular geneticist at Brigham and Women's Hospital and Harvard Medical School. The study also used sophisticated statistical modeling by simulation, designed by Peter Kraft, PhD, at the Harvard School of Public Health. Researchers from the University of Mississippi Medical Center contributed Jackson Heart Study data.

This work was supported by the National Human Genome Research Institute, the Howard Hughes Medical Institute, the National Heart, Lung and Blood Institute and the National Institute on Minority Health and Health Disparities.

Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 4.2 million annual patient visits and nearly 46,000 inpatient stays, is the largest birthing center in Massachusetts and employs nearly 16,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Brigham Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, more than 3,000 researchers, including physician-investigators and renowned biomedical scientists and faculty supported by nearly $666 million in funding. For the last 25 years, BWH ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative as well as the TIMI Study Group, one of the premier cardiovascular clinical trials groups. For more information, resources and to follow us on social media, please visit BWH's online newsroom.

Brigham and Women's Hospital

Related Cancer Articles:

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
More Cancer News and Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...